Should I order empagliflozin (Jardiance) for a newly diagnosed adult with type 2 diabetes who has no contraindications and an eGFR ≥45 mL/min/1.73 m²?

Should You Order Empagliflozin (Jardiance) for a Newly Diagnosed Type 2 Diabetic?

Yes, you should strongly consider ordering empagliflozin (Jardiance) for a newly diagnosed adult with type 2 diabetes who has an eGFR ≥45 mL/min/1.73 m² and no contraindications, as SGLT2 inhibitors with proven cardiovascular and kidney benefits are now recommended as foundational therapy alongside or even independent of metformin. 1

Current Guideline Recommendations

The 2022 ADA/KDIGO consensus and 2025 ADA Standards of Care represent a paradigm shift in diabetes management:

• SGLT2 inhibitors with proven kidney or cardiovascular benefit are recommended for patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m², even at diagnosis 1
• For newly diagnosed patients, an SGLT2 inhibitor can be initiated independent of A1C level and with or without metformin, particularly when considering long-term cardiovascular and kidney protection 1
• The 2020 KDIGO guidelines specifically recommend treating patients with type 2 diabetes, CKD, and eGFR ≥30 mL/min/1.73 m² with an SGLT2 inhibitor (Grade 1A recommendation) 1

Empagliflozin-Specific Considerations

Dosing and eGFR Requirements

For your newly diagnosed patient with eGFR ≥45 mL/min/1.73 m²:

• Start empagliflozin 10 mg once daily in the morning, with or without food 2
• May increase to 25 mg daily if additional glycemic control is needed 2
• Empagliflozin can be initiated at eGFR ≥30 mL/min/1.73 m² for glycemic control, though FDA labeling notes use is not recommended below 45 mL/min/1.73 m² for glucose lowering 1, 2
• Once initiated, continue empagliflozin even if eGFR falls below the initiation threshold, as cardiovascular and kidney benefits persist 1

Important Distinction from Other SGLT2 Inhibitors

Empagliflozin has more restrictive eGFR requirements compared to other SGLT2 inhibitors:

• Dapagliflozin can be initiated down to eGFR 25 mL/min/1.73 m² 1
• Canagliflozin can be initiated down to eGFR 30 mL/min/1.73 m² in patients with albuminuria >300 mg/day 1
• Empagliflozin initiation is not recommended below eGFR 45 mL/min/1.73 m² per FDA labeling, though guidelines support use down to eGFR 30 mL/min/1.73 m² 1, 2

Clinical Benefits Beyond Glucose Control

Cardiovascular Protection

• Empagliflozin reduces cardiovascular death by 38% and all-cause mortality by 32% in patients with type 2 diabetes and established cardiovascular disease 3
• Reduces major adverse cardiovascular events (MACE) by 14% 3
• Reduces hospitalization for heart failure 3

Kidney Protection

• Glucose-lowering efficacy decreases as eGFR declines, but cardiovascular and kidney benefits are preserved 1
• SGLT2 inhibitors reduce albuminuria and slow eGFR decline 1

Additional Benefits

• Weight loss of approximately 2-3 kg 4
• Systolic blood pressure reduction of 3-5 mmHg 4
• No intrinsic risk of hypoglycemia when used alone 4

Safety Monitoring and Patient Education

Before Initiating Empagliflozin

• Assess renal function (eGFR must be ≥45 mL/min/1.73 m² for initiation per FDA label, though ≥30 mL/min/1.73 m² per guidelines) 2
• Correct volume depletion before starting 2
• If patient is on insulin or sulfonylurea and well-controlled, consider reducing insulin by 20% or sulfonylurea by 50% to prevent hypoglycemia 1

Patient Education Points

• Educate about genital mycotic infections (occur in 6% vs 1% placebo), which are usually mild and easily treated 1
• Teach recognition of diabetic ketoacidosis symptoms (nausea, vomiting, weakness), which can occur even with blood glucose 150-250 mg/dL 1, 2
• Advise to withhold empagliflozin during prolonged fasting, surgery, or critical illness 1
• Educate about volume depletion symptoms (lightheadedness, orthostasis, weakness) 1
• Maintain at least low-dose insulin if on insulin therapy to reduce ketoacidosis risk 1

Ongoing Monitoring

• Monitor kidney function regularly; expect a reversible eGFR decrease of 3-5 mL/min/1.73 m² initially, which is not an indication to stop 1
• Monitor for volume depletion, especially in elderly patients ≥75 years (volume depletion occurs in 4.4% vs 2.1% placebo) 2
• Consider reducing thiazide or loop diuretic doses before starting empagliflozin 1

Common Pitfalls to Avoid

• Don't wait for A1C to rise before initiating—cardiovascular and kidney benefits justify early use 1
• Don't discontinue empagliflozin if eGFR drops below 45 mL/min/1.73 m² after initiation—continue for cardiovascular and kidney protection 1
• Don't use empagliflozin as a threat or sign of failure—frame it as proactive protection against complications 1
• Don't forget to educate about ketoacidosis risk, especially during illness or fasting 1, 2
• Avoid canagliflozin specifically in patients with prior amputation, severe peripheral arterial disease, neuropathy, or diabetic foot ulcers 1

Contraindications

• Hypersensitivity to empagliflozin (including angioedema) 2
• Patients on dialysis 2
• Type 1 diabetes (increased ketoacidosis risk) 2